会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Genetic markers and methods for detecting and treating cancers
    • 用于检测和治疗癌症的遗传标记和方法
    • US20090054363A1
    • 2009-02-26
    • US11907697
    • 2007-10-16
    • Chin-Tarng LinHan-Chung WuDah-Yeou Huang
    • Chin-Tarng LinHan-Chung WuDah-Yeou Huang
    • A61K31/70A61P35/00C12Q1/68
    • C12Q1/6886C12Q2600/118C12Q2600/158
    • The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and/or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue. Furthermore, the identified genetic marker SOX5 and/or SPARC can also be used for cancer targeted therapy, because down regulation of SOX5 and/or up regulation of SPARC expression in NOD-SCID can retard tumor growth and inhibit cell proliferation, migration, invasion and metastasis.
    • 本发明提供用于远处转移的遗传标记物SOX5和SPARC,并且对癌症患者的高潜力检测的预后差。 此外,本发明还提供了一种预测远端转移癌症患者和预后不良的潜在风险的方法。 该方法包括从患者获得组织样本,评估样品中SOX5和/或SPARC遗传标记的表达水平; 并比较遗传标记的表达水平与非癌组织的表达水平。 当SOX5的表达水平较高时,或者当SPARC的表达水平低于非癌组织的表达水平时,患者被确定为具有远处转移的高风险或不良预后。 此外,所鉴定的遗传标记SOX5和/或SPARC也可用于癌症靶向治疗,因为SOX5的下调和/或NOD-SCID中SPARC表达的上调可以延缓肿瘤生长并抑制细胞增殖,迁移,侵袭和 转移。
    • 4. 发明申请
    • Peptides specific for hepatocellular carcinoma cells and applications thereof
    • 特异于肝细胞癌细胞的肽及其应用
    • US20090136418A1
    • 2009-05-28
    • US12292401
    • 2008-11-18
    • Han-Chung WuChin-Tarng LinAlbert Lo
    • Han-Chung WuChin-Tarng LinAlbert Lo
    • A61K51/00C12N15/11C07K7/00C07K16/18G01N33/574A61K9/127A61K38/10
    • G01N33/57438A61K38/00C07K7/08
    • Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC.
    • 肝细胞癌(HCC)是全球第四大癌症死亡原因。 不断开发从增加分子肿瘤学知识得出的新型治疗策略来治愈这种疾病。 在这里,我们使用噬菌体展示来鉴定新型肽,包括特异性结合HCC细胞的(SP94)。 在体外,噬菌体克隆PC94结合HCC细胞系。 在体内,PC94特异性地归巢于肿瘤组织,而不是携带人类HCC异种移植物的SCID小鼠中的正常内脏器官。 归巢能力可以被合成肽SP94竞争性抑制。 PC94定位于肿瘤组织,但在SP94竞争的肿瘤组织或正常器官中不能检测到。 此外,PC94在HCC患者手术标本中识别肿瘤组织,但不识别非肿瘤组织,阳性率为61.3%(19/31)。 通过SP94和脂质体多柔比星的缀合,靶向药物递送系统通过增强肿瘤细胞凋亡和减少肿瘤血管生成来增强对HCC异种移植物的治疗效果。 我们的研究结果表明,SP94可以改善晚期HCC患者的全身治疗。